Hello Nature Readers, would you like to have this briefing in your inbox every day for free? Register here
Two pharmaceutical companies have stopped clinical trials of Huntington’s disease (HD) gene therapiesfollowing unsatisfactory drug performance. The researchers hoped that treatment – known as antisense oligonucleotides (ASO) – would alter the play of HD, an incurable genetic condition that affects cognition, behavior, and movement. But the mutual announcements between Roche and Wave Life Sciences dealt a severe blow to those affected. “It’s the saddest possible outcome,” says neurologist Claudia Testa.
This indicates a rising level of neutrons from an inaccessible room at the Chernobyl nuclear power plant fission reactions are smoldering again at the site of the 1986 disaster. “It’s like coals in a grill pit,” says nuclear materials chemist Neil Hyatt. The room buried under the concrete contains part of the solidified lava, which contains a large part of the reactor’s uranium fuel. The mechanism that governs the reaction, how it could develop and how to suppress it, are all open questions.
Properties and opinion
Devastating sea waves are destroying ecosystems, bleaching corals and endangering key fisheries. A gloomy example was called The Blob: an area of warm, low-nutrient water in the Pacific Northwest that lasted three years and decimated populations of plankton, fish and seabirds. Scientists are pushing the science of oceanic predictions forwardand seek the development of tools to help fisheries policy makers and policy makers respond to these painful symptoms of a warming world.
Four decades after the AIDS epidemic began, the results of a small clinical trial suggest some progress towards a vaccine that protects against HIV. Researchers announced this at the February AIDS conference 35 out of 36 people who received a new HIV vaccine produced antibodies that could help their immune system repel the infection. However, the findings have not yet been reviewed and experts warn that the vaccine is still a long way off. HIV has proven to be an elusive enemy for immunization due to its rapid rate of mutation – but lack of funding is also a major problem. “If the company really appreciated the HIV vaccine, we would conduct several efficacy studies in parallel, as was the case with COVID,” says virologist José Esparza. “Dear, yes.” But the cost of the HIV epidemic was enormous. “